➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Express Scripts
Dow
AstraZeneca
Moodys

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DROSPIRENONE; ETHINYL ESTRADIOL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Drospirenone; Ethinyl Estradiol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00413062 ↗ Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722) Completed Merck Sharp & Dohme Corp. Phase 3 2006-06-01 The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00511199 ↗ Efficacy and Safety of the Combined Oral Contraceptive (COC) NOMAC-E2 Compared to a COC Containing DRSP/EE (292001)(COMPLETED)(P05724) Completed Merck Sharp & Dohme Corp. Phase 3 2006-05-01 The primary purpose of this study is to assess contraceptive efficacy, vaginal bleeding patterns (cycle control), general safety and acceptability of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) in a large group of women aged 18-50 years.
NCT00511433 ↗ Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723) Completed Merck Sharp & Dohme Corp. Phase 3 2006-10-01 The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.
NCT00567164 ↗ Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ Completed Bayer Phase 3 2007-10-01 The purpose of this study is to determine whether the study drug is safe and effective.
NCT00633360 ↗ The Oral Contraceptive Pill for Premenstrual Worsening of Depression Completed Massachusetts General Hospital N/A 2008-02-01 To determine if augmentation with the oral-contraceptive pill containing drospirenone and ethinyl estradiol is more effective than placebo in the treatment of premenstrual breakthrough of depression.
NCT00640224 ↗ Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 4 2005-03-01 The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory markers, vascular markers and bone development in overweight adolescent females with polycystic ovary syndrome (PCOS).
NCT00640224 ↗ Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study Completed Children's Hospital of Pittsburgh Phase 4 2005-03-01 The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory markers, vascular markers and bone development in overweight adolescent females with polycystic ovary syndrome (PCOS).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Drospirenone; Ethinyl Estradiol

Condition Name

Condition Name for Drospirenone; Ethinyl Estradiol
Intervention Trials
Contraception 10
Healthy 4
Polycystic Ovary Syndrome 4
Acne Vulgaris 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Drospirenone; Ethinyl Estradiol
Intervention Trials
Polycystic Ovary Syndrome 4
Acne Vulgaris 3
Syndrome 3
Dysmenorrhea 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Drospirenone; Ethinyl Estradiol

Trials by Country

Trials by Country for Drospirenone; Ethinyl Estradiol
Location Trials
United States 82
China 19
Germany 14
United Kingdom 6
Austria 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Drospirenone; Ethinyl Estradiol
Location Trials
California 5
Massachusetts 5
Pennsylvania 5
Florida 4
Arizona 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Drospirenone; Ethinyl Estradiol

Clinical Trial Phase

Clinical Trial Phase for Drospirenone; Ethinyl Estradiol
Clinical Trial Phase Trials
Phase 4 7
Phase 3 15
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Drospirenone; Ethinyl Estradiol
Clinical Trial Phase Trials
Completed 20
Not yet recruiting 3
Recruiting 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Drospirenone; Ethinyl Estradiol

Sponsor Name

Sponsor Name for Drospirenone; Ethinyl Estradiol
Sponsor Trials
Bayer 12
Merck Sharp & Dohme Corp. 3
Massachusetts General Hospital 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Drospirenone; Ethinyl Estradiol
Sponsor Trials
Industry 22
Other 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Boehringer Ingelheim
Merck
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.